The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2020 | Belantamab mafodotin: ocular toxicity
With reference to the DREAMM-2 (NCT03525678) trial, Sagar Lonial, MD, Winship Cancer Institute of Emory University, Atlanta, GA, delineates the potential for ocular toxicities in multiple myeloma patients treated with antibody-drug conjugate belantamab mafodotin. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Sagar Lonial, MD, has done consultancy work for Takeda, Celgene, BMS, Janssen, GSK, Abbvie, Novartis and Janssen; and has been a member of a board of directors for TG Therapeutics.
